Following are specific recommended plasma levels and actions for common bleeding problems and clinical situations which occur with Hemophilia B, also known as Factor IX Deficiency: Assess situation ...

VON Willebrand's disease is manifested by a deficiency of factor VIII (antihemophilic factor) and a prolonged bleeding time and is inherited as an autosomal dominant trait of variable penetrance. 1 ...

A commercially prepared plasma concentrate was administered in six infusions to four patients with factor IX deficiency. All showed a distinct rise in the factor IX level. On the basis of the ...

Factor IX concentrate products ( Table 1) may be used to manage an acute hemorrhage or to decrease the risk of bleeding associated with surgery in patients with hemophilia B. Before factor IX ...

Different types of assays led to different results in measures of factor IX variant FIX-R338L, the authors found. A new field study could help clinicians better interpret laboratory measurements of ...

Hemophilia B is a genetic disorder that affects how well your blood clots. Treatment includes supplementing the protein factor IX, but new therapies may offer alternative ways to manage factor IX ...

Gene therapy for hemophilia B allowed almost three-fourths of patients to discontinue prophylactic factor IX therapy with no increase in bleeding, results of the pivotal BENEGENE-2 trial showed. The ...

The projected cost reductions held both for patients switching from a different extended-half-life product and for patients switching from a standard-half-life product. Switching patients with ...

Please provide your email address to receive an email when new articles are posted on . A single infusion of verbrinacogene setparvovec resulted in normal factor IX levels among all 10 men who ...

The risk of an immune response to the coagulation factor IX (F.IX) transgene product is a concern in gene therapy for the X-linked bleeding disorder hemophilia B. In order to investigate the mechanism ...

Pfizer PFE announced that the FDA has approved its anti-TFPI inhibitor Hympavzi (marstacimab) for the treatment of two ...

DSM Pharmaceutical Products signed an agreement for commercial supply with Netherlands-based Sanquin Blood Supply Foundation covering the manufacture of a monoclonal antibody used to recover and ...